Lakefront Biotherapeutics (GLPGF) Total Liabilities (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Total Liabilities for 14 consecutive years, with $139.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Liabilities fell 89.6% year-over-year to $139.4 million in Q1 2026; TTM through Mar 2026 was $139.4 million, a 89.6% decrease from a year earlier, with the FY2025 full-year figure at $192.8 million, down 85.62% from the prior year.
• Total Liabilities was $139.4 million for Q1 2026 at Lakefront Biotherapeutics, down from $198.6 million in the prior quarter.
• Over five years, Total Liabilities peaked at $2.8 billion in Q1 2022 and troughed at $139.4 million in Q1 2026.
• A 5-year average of $1.5 billion and a median of $1.4 billion in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities retreated 13.44% in 2025 and plunged 89.6% in 2026, its largest moves.
• Over 5 years, Total Liabilities stood at $2.3 billion in 2022, then slipped by 25.41% to $1.7 billion in 2023, then declined by 21.23% to $1.3 billion in 2024, then tumbled by 84.99% to $198.6 million in 2025, then slipped by 29.83% to $139.4 million in 2026.
• The last three Total Liabilities figures came in at $139.4 million (Q1 2026), $198.6 million (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.